Sera Announces Publication Acceptance for PRIME Study

Core Insights - The PRIME study, a significant research initiative on preterm birth, has been accepted for publication in a peer-reviewed journal, following its presentation at a medical conference earlier this year [1][2] - Sera Prognostics, Inc. focuses on enhancing maternal and neonatal health through innovative pregnancy biomarker information [1][3] Company Overview - Sera Prognostics is a health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care [3] - The company's PreTRM Test is the only broadly validated, commercially available blood-based biomarker test for early risk prediction of spontaneous preterm birth [4] Product Details - The PreTRM Test analyzes proteins in the blood to predict preterm birth risk in asymptomatic singleton pregnancies, allowing for informed clinical decisions [4] - The test is ordered by medical professionals and provides risk assessments during weeks 18 to 20 of pregnancy [4]